Your session is about to expire
← Back to Search
Behavioural Intervention
Smart PSA Screening for Prostate Cancer
N/A
Waitlist Available
Led By Peter Gann, MD, ScD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
PCP employed by MSHC who provides care for male adult patients
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months after intervention
Awards & highlights
Study Summary
This trial is testing whether or not these guidelines, along with patient navigation, can help improve care for men with prostate cancer.
Who is the study for?
This clinical trial is for male adult patients under the care of primary care physicians (PCPs) employed by MSHC. It's focused on those who might need prostate cancer screening, specifically using PSA levels as an indicator.Check my eligibility
What is being tested?
The study is testing new guidelines for PSA screening to detect prostate cancer. This includes determining the best age to start and stop screenings, how often they should be done, and what PSA level should prompt a biopsy.See study design
What are the potential side effects?
Since this trial involves completing surveys rather than medical treatments or drugs, there are no direct physical side effects associated with participating in this study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months after intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months after intervention
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Benefit and harm analysis 12 months prior to the intervention
Activation Analysis
Number of PCPs that have confidence in discussing prostate issues 12 months prior to the intervention
+13 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: PCP Evaluation of Smart PSA Screening GuidelinesExperimental Treatment1 Intervention
Completing surveys at baseline, 3, 6, 9 and 12 months
Find a Location
Who is running the clinical trial?
University of Illinois at ChicagoLead Sponsor
609 Previous Clinical Trials
1,559,260 Total Patients Enrolled
10 Trials studying Prostate Cancer
1,019 Patients Enrolled for Prostate Cancer
Peter Gann, MD, ScDPrincipal Investigator - University of Illinois at Chicago
University of Illinois at Chicago
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a primary care provider at MSHC for adult men.
Research Study Groups:
This trial has the following groups:- Group 1: PCP Evaluation of Smart PSA Screening Guidelines
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still opportunities to become a participant in this exploration?
"As evidenced by the clinicaltrials.gov records, this study is no longer recruiting patients as of July 14th 2022. Initially posted on December 17 2021, it has since been superseded by 1,322 other trials that are currently accepting participants."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger